

To Whom it may concern,

**SKUs:**

**CLINDAMYCIN C 150mg CAP 1x24 BLST GB**

**CLINDAMYCIN C 150mg CAP 1x100**

**CLINDAMYCIN C 75mg CAP 1x24**

We write to inform you that from the beginning of March 2025, Pfizer Limited will commence the supply of CLINDAMYCIN C 150mg CAP 1x24 BLST GB, CLINDAMYCIN C 75mg CAP 1x24 and CLINDAMYCIN C 150mg CAP 1x100, generic versions of DALACIN® C (clindamycin hydrochloride) capsules 75 mg 1 x24, 150 mg 1 x 100 and 150mg CAP 1x24 BLST GB. We will continue to offer both the branded and generic presentations, for a short period of transition, after which the brand will no longer be routinely available.

Pfizer Ltd will be adding the below products to its portfolio. There will be no alterations to the packaging, except for the packaging referring to the generic name Clindamycin C replacing the branded name DALACIN® C.

We recommend you update your ordering systems with the new presentations and codes below:

Product (PREVIOUS)	Pip Code	NHS List Price	Product (NEW)	EAN Code	Pip Code	NHS List Price
DALACIN® C 150mg CAP 1x24 BLST GB	213-5903	£13.72	Clindamycin C 150mg CAP 1x24 BLST GB	5 415062 122433	128-0882	£13.72
DALACIN® C CAP 150mg 1 x 100	006-7546	£55.08	Clindamycin C 150mg CAP 1x 100	5 415062 122419	128-0890	£55.08
DALACIN® C 75mg CAP 1 x 24	213-5911	£7.45	Clindamycin C 75mg CAP 1 x 24	5 415062 122426	128-0908	£7.45

Prices shown are exclusive of VAT.

Orders: The new product will be distributed in the same way via Alliance ordering systems, please use Pip code(s) in above table.

PP-DAL-GBR-0022

January 2025

Pfizer recognises and is committed to a sustainable supply of these 'Older' Medicines for UK patients. As part of our ongoing Established Older Medicines strategy, we will review market need and introduce generic alternatives, where appropriate, to our portfolio.

Should you require any further information please contact **Pfizer Customer Service** on **0345 608 8866** or **Freephone 0800 032 7907** or if you have any questions relating to the enclosed debranding, please don't hesitate to contact me.

**Further clinical information if required:**

If you are asked any questions on this matter, please refer your customer to Pfizer Medical Information on 01304 61 61 61 (or via e-mail at [Medical.Information@pfizer.com](mailto:Medical.Information@pfizer.com)).

The SmPC is available on EMC.

Yours faithfully,



Doug Tootell

Commercial Tenders & Contracts Director

PP-DAL-GBR-0022

January 2025

# Examination/Medical Review Certificate UK

**Name** UK\_CP\_Clindamycin Caps DEBRANDING LAUNCH TRADE LETTER\_Jan\_2025 V2  
**Document Number** PP-DAL-GBR-0022

## EXAMINED AND APPROVED FOR USE

The below medical signatory has examined the electronic artwork of this material and in their belief it and the arrangements it relates to, are in accordance with Pfizer policies and the ABPI Code of Practice.

Medical Affairs	Name: Catherine Record Signature Date: 30-Jan-2025 09:16:26 GMT+0000 Reason: Examined and approved for use
-----------------	--